We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTWR
176
PUT
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$1.17M 0.05%
133
– –
LLY icon
177
PUT
Eli Lilly
LLY
$1.09T
$1.16M 0.05%
+160
New +$11.4K
ACHN
178
DELISTED
Achillion Pharmaceuticals
ACHN
$1.12M 0.05%
113,704
-890,483
-89% -$11.1M
AXGN icon
179
Axogen
AXGN
$2.19B
$1.11M 0.05%
+318,136
New +$1.09M
EXEL icon
180
CALL
Exelixis
EXEL
$14.2B
$1.11M 0.05%
4,319
+2,305
+114% +$5.35K
NSPR icon
181
InspireMD
NSPR
$32.1M
$1.08M 0.04%
+1
New +$3.95M
VNDA icon
182
Vanda Pharmaceuticals
VNDA
$310M
$1.05M 0.04%
+113,165
New +$1.28M
CTIC
183
CALL
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.04M 0.04%
575
-121
-17% -$2.72K
BDSI
184
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.03M 0.04%
+985
New +$13.5K
SKBI
185
DELISTED
SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
$999K 0.04%
255,435
-58,932
-19% -$250K
XOMA
186
CALL
DELISTED
Xoma
XOMA
$996K 0.04%
137
-138
-50% -$10.1K
VIRX
187
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$993K 0.04%
+19
New +$9.59K
RNVA
188
DELISTED
Rennova Health, Inc.
RNVA
$981K 0.04%
+200
New +$1.04M
SGYPW
189
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$980K 0.04%
+2,121
New +$1.74K
PLUR icon
190
PUT
Pluri
PLUR
$18.1M
$966K 0.04%
43
+33
+330% +$7.75K
NBIX icon
191
PUT
Neurocrine Biosciences
NBIX
$18.4B
$957K 0.04%
241
-1,373
-85% -$49.1K
BCRX icon
192
CALL
BioCryst Pharmaceuticals
BCRX
$2.48B
$952K 0.04%
+1,054
New +$10.9K
KYTH
193
PUT
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$943K 0.04%
+188
New +$7.89K
RXII
194
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$941K 0.04%
6,772
+172
+3% +$23.9K
MNK
195
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$922K 0.04%
+7,280
New +$832K
GWPH
196
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$911K 0.04%
+100
New +$8.12K
FOCL
197
PUT
EDAP TMS S.A.
FOCL
$227M
$906K 0.04%
2,687
+2,519
+1,499% +$8.44K
SSKN
198
DELISTED
Strata Skin Sciences
SSKN
$882K 0.04%
6,863
-5,122
-43% -$506K
CSLT
199
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$841K 0.04%
+1,084
New +$9.28K
CVM.WS
200
DELISTED
Cel-Sci Corp Series S
CVM.WS
$840K 0.04%
2,624,375
-440,370
-14% -$99.3K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.